ARCT MEXC RealStocks
Own real ARCT shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 05:55:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Arcturus Therapeutics Holdings Inc. (ARCT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.44, with a market capitalization of $270.64M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.50 to $17.96. This page covers its latest market performance, valuation, price trends and company information.
$270.64M | |
$9.03 | |
$9.33 | |
$8.41 | |
$9.31 | |
353.59K | |
1.01M | |
-- | |
$17.96 | |
$5.50 | |
-- | |
-- |
Arcturus Therapeutics Holdings Inc. (ARCT) last closed at $8.44 as of 2026-11-13 00:31:00, down 9.45% ($0.88) from the previous close of $9.31.
During the latest regular trading session, ARCT traded between $8.42 and $9.33, with a volume of 353.59K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Arcturus Therapeutics Holdings Inc. (ARCT) moved from $9.54 to $8.44, representing a decline of 11.57% ($1.10).
The stock traded between $8.42 and $10.89 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 691.26 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 23.6%
ARCT is currently trading at $8.44, placing it 23.6% of the way from its 52-week low of $5.50 to its 52-week high of $17.96. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 111 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Arcturus Therapeutics Holdings Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Arcturus Therapeutics Holdings Inc. (ARCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ARCT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ARCT shares and USD.
ARCT Shares to USD
1.00 ARCT shares = 8.436 USD
Calculations are estimates based on the latest available price and are for reference only.